Equivalent gene expression profiles between glatopa™ and copaxone®

Josephine S. D'Alessandro, Jay Duffner, Joel Pradines, Ishan Capila, Kevin Garofalo, Ganesh Kaundinya, Benjamin M. Greenberg, Daniel Kantor, Tanmoy C. Ganguly

Research output: Contribution to journalArticlepeer-review

12 Scopus citations

Abstract

Glatopa™is a generic glatiramer acetate recently approved for the treatment of patients with relapsing forms of multiple sclerosis. Gene expression profiling was performed as a means to evaluate equivalence of Glatopa and Copaxone1. Microarray analysis containing 39,429 unique probes across the entire genome was performed in murine glatiramer acetate-responsive Th2-polarized T cells, a test system highly relevant to the biology of glatiramer acetate. A closely related but nonequivalent glatiramoid molecule was used as a control to establish assay sensitivity. Multiple probe-level (Student's t-test) and samplelevel (principal component analysis, multidimensional scaling, and hierarchical clustering) statistical analyses were utilized to look for differences in gene expression induced by the test articles. The analyses were conducted across all genes measured, as well as across a subset of genes that were shown to be modulated by Copaxone. The following observations were made across multiple statistical analyses: the expression of numerous genes was significantly changed by treatment with Copaxone when compared against media-only control; gene expression profiles induced by Copaxone and Glatopa were not significantly different; and gene expression profiles induced by Copaxone and the nonequivalent glatiramoid were significantly different, underscoring the sensitivity of the test system and the multiple analysis methods. Comparative analysis was also performed on sets of transcripts relevant to T-cell biology and antigen presentation, among others that are known to be modulated by glatiramer acetate. No statistically significant differences were observed between Copaxone and Glatopa in the expression levels (magnitude and direction) of these glatiramer acetate-regulated genes. In conclusion, multiple methods consistently supported equivalent gene expression profiles between Copaxone and Glatopa.

Original languageEnglish (US)
Article numbere0140299
JournalPloS one
Volume10
Issue number10
DOIs
StatePublished - Oct 16 2015

ASJC Scopus subject areas

  • General

Fingerprint

Dive into the research topics of 'Equivalent gene expression profiles between glatopa™ and copaxone®'. Together they form a unique fingerprint.

Cite this